Cetuximab (PBS)

Cetuximab (PBS) is a human IgG1 monoclonal antibody that can inhibit EGFR. The SPR method measured the Kd value of Cetuximab for EGFR to be 0.201 nM; Cetuximab has a highly effective anti-tumor effect[1].

12352203

EGFR; Radionuclide-Drug Conjugates (RDCs)

Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Cancer-Kinase/protease

Cancer

99.3

[Cetuximab(PBS)]

(145.54 kDa)

[1]Goldstein, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clinical cancer research: an official journal of the American Association for Cancer Research 1.11 (1995) : 1311-1318.|[2]Gustafsson H, et al. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model. Cell Biochem Biophys. 2017 Jul 29.|[3]Huang SM, et al. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck. Cancer Res. 1999 Apr 15;59 (8) :1935-40.

Dry Ice

-80°C

http://file.medchemexpress.com/batch_PDF/HY-P9S0008/Cetuximab-PBS-SDS-MedChemExpress.pdf

Inhibitory Antibodies

No Development Reported